Pfizer (PFE) CEO expects to launch next-gen obesity assets acquired through Metsera buyout in 2028

Pfizer's CEO projecting the launch of next-generation obesity treatments from the Metsera acquisition in 2028 suggests a strategic focus on a high-demand therapeutic area.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

White House says US President Trump supports Fed independence

German Finance Minister says they do not have time to lose on rare earths; will be central topic under G7 French Presidency

Pfizer (PFE) CEO expects to launch next-gen obesity assets acquired through Metsera buyout in 2028

White House says Iran's public statements differ from private messages sent to the US

White House says Trump is to visit Ford (F) factory on Tuesday, Fox News report

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This timeline indicates a long-term commitment to enhancing Pfizer's product pipeline, potentially positioning the firm advantageously in a competitive market focused on obesity management. Watch for how this might influence investor sentiment and stock performance as the launch date approaches.

Related headlines

The whole workspace, free to try.

Try it free